Pfizer Issues “Damage Control” statement in aftermath of Veritas Video, shoot themselves in the foot!

In the wake of the recent “viral” Project Veritas bombshell relating to deliberate virus mutation, Pfizer has issued a response.

We scrutinize it, and we include John Campbell’s “terrified” analysis, with a nice ending quotation!

Martin Harris 29/1/23

Below is Pfizer’s release, please note the portion of text that I have highlighted which essentially confirms the Veritas interview claims. Note that “directed evolution” is essentially engineered mutation. Semantics on Pfizers part. But we aren’t easily hoodwinked.

Pfizer Responds to Research Claims

Friday, January 27, 2023 – 08:00pm

New York, N.Y., January 27, 2023 – Allegations have recently been made related to gain of function and directed evolution research at Pfizer and the company would like to set the record straight.  

In the ongoing development of the Pfizer-BioNTech COVID-19 vaccine, Pfizer has not conducted gain of function or directed evolution research.  Working with collaborators, we have conducted research where the original SARS-CoV-2 virus has been used to express the spike protein from new variants of concern. This work is undertaken once a new variant of concern has been identified by public health authorities. This research provides a way for us to rapidly assess the ability of an existing vaccine to induce antibodies that neutralize a newly identified variant of concern. We then make this data available through peer reviewed scientific journals and use it as one of the steps to determine whether a vaccine update is required.   

In addition, to meet U.S. and global regulatory requirements for our oral treatment, PAXLOVID™, Pfizer undertakes in vitro work (e.g., in a laboratory culture dish) to identify potential resistance mutations to nirmatrelvir, one of PAXLOVID’s two components.  With a naturally evolving virus, it is important to routinely assess the activity of an antiviral.  Most of this work is conducted using computer simulations or mutations of the main protease–a non-infectious part of the virus.  In a limited number of cases when a full virus does not contain any known gain of function mutations, such virus may be engineered to enable the assessment of antiviral activity in cells. In addition, in vitro resistance selection experiments are undertaken in cells incubated with SARS-CoV-2 and nirmatrelvir in our secure Biosafety level 3 (BSL3) laboratory to assess whether the main protease can mutate to yield resistant strains of the virus.  It is important to note that these studies are required by U.S. and global regulators for all antiviral products and are carried out by many companies and academic institutions in the U.S. and around the world.

Fact-based information rooted in sound science is vitally important to overcoming the COVID-19 pandemic and Pfizer remains committed to transparency and helping alleviate the devastating burden of this disease.

SOURCE: Pfizer Responds to Research Claims | Pfizer

This is what Pfizer are responding to:

As Dr. Campbell points out in the video below, it appears that while Pfizer denies “gain of function” research, they appear to be revealing that actually ARE mutating the virus as Veritas claim in their video and that they ARE then using the results to create “vaccine upgrades”.